Mirum Pharmaceuticals Reports Strong 2025 Financials, Expands Pipeline with Bluejay Acquisition, and Defends Key Patents

summarizeSummary

Mirum Pharmaceuticals reported significantly improved financial results for 2025, driven by strong product sales, while strategically expanding its pipeline through the Bluejay acquisition and actively defending its key Livmarli patents.

check_boxKey Events

• Strong 2025 Financial Performance

  Net loss significantly reduced to $23.4 million for the year ended December 31, 2025, compared to $87.9 million in 2024. Product sales grew 55% to $521.3 million in 2025 from $336.4 million in 2024, driven by continued commercialization of Livmarli and Bile Acid Medicines.

• Strategic Bluejay Therapeutics Acquisition

  Completed the acquisition of Bluejay Therapeutics, Inc. on January 23, 2026, adding worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody for chronic hepatitis D virus (HDV) infection. Topline results from registration-enabling Phase 3 trials (AZURE-1 and AZURE-4) are expected in the second half of 2026.

• Successful Financing for Acquisition

  Immediately following the Bluejay acquisition, the company raised approximately $268.5 million in gross proceeds through a private placement of 3,385,149 shares of common stock and pre-funded warrants to purchase 536,412 shares.

• LIVMARLI Patent Defense Initiated

  Filed patent infringement lawsuits against generic manufacturers in December 2025, securing a 30-month stay on final regulatory approval for generic versions of LIVMARLI until March 29, 2029, protecting a key revenue stream.

auto_awesomeAnalysis

Mirum Pharmaceuticals delivered a strong annual report for 2025, showcasing significant financial improvements and strategic advancements. The company substantially reduced its net loss and achieved robust product sales growth, indicating a positive trajectory for its commercialized medicines. A key development is the recent acquisition of Bluejay Therapeutics, which adds a late-stage asset, brelovitug, to Mirum's pipeline, expanding its reach into chronic hepatitis D virus (HDV) treatment. This acquisition was supported by a significant private placement, bolstering the company's capital resources. Furthermore, Mirum has taken crucial steps to protect its flagship product, LIVMARLI, by initiating patent infringement lawsuits against generic manufacturers, securing a 30-month stay on generic approvals. This proactive defense is vital for maintaining revenue streams. The progress of other pipeline candidates, such as volixibat receiving Breakthrough Therapy designation, further strengthens the company's long-term growth prospects. The overall picture is one of strong operational execution, strategic expansion, and effective risk management.